Video
Dr. Le on the Design of the VISION Trial in METex14-Mutant NSCLC
Author(s):
Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the phase 2 VISION trial in MET exon 14 skipping (METex14)—mutant non–small cell lung cancer (NSCLC).
Given the rationale to support the use of the tepotinib (Tepmetko) in this patient population, investigators launched a single-arm design rather than a randomized trial with chemotherapy, Le explains.
The ongoing VISION trial is a global trial that will determine whether tepotinib has utility as a targeted therapy in patients with this rare alteration, Le concludes.
